Rani Therapeutics Holdings, Inc.
RANI
Rank in Stocks
#23929
Rani Therapeutics Holdings, Inc. functions as a clinical-stage... Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Share Price
$0.5743
Last synced: 2026-11-09
Market Cap
$37.51M
Change (1 day)
5.03%
Change (1 year)
-70.40%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Rani Therapeutics Holdings, Inc. (RANI)
Category
Healthcare
EPS for Rani Therapeutics Holdings, Inc. (RANI)
EPS as of June 2026 TTM: $-0.27
According to Rani Therapeutics Holdings, Inc.'s latest financial reports, its current EPS (TTM) is $-0.27. At the end of 2025 the company had an EPS of $-0.45, an increase over its 2024 EPS of $-1.05.
EPS history for Rani Therapeutics Holdings, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.27 | -40.00% |
| 2025 | $-0.45 | -57.14% |
| 2024 | $-1.05 | -21.05% |
| 2023 | $-1.33 | 3.91% |
| 2022 | $-1.28 | 204.76% |
| 2021 | $-0.42 | -50.59% |
| 2020 | $-0.85 | -37.04% |
| 2019 | $-1.35 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -5,900.00% |
US
|
|
| $-7.07 | 2,518.52% |
US
|
|
| $-5.29 | 1,859.26% |
AU
|
|
| $12.88 | -4,870.41% |
BE
|
|
| $21.56 | -8,085.19% |
NL
|
Questions about Rani Therapeutics Holdings, Inc.'s earnings per share (EPS)
What is Rani Therapeutics Holdings, Inc.'s earnings per share (EPS)?
Rani Therapeutics Holdings, Inc.'s earnings per share (EPS) over the last twelve months is $-0.27, as of Jun 2026.
What was Rani Therapeutics Holdings, Inc.'s earnings per share (EPS) in 2025?
In 2025, Rani Therapeutics Holdings, Inc.'s earnings per share (EPS) was $-0.45, compared with $-1.05 in 2024.
How has Rani Therapeutics Holdings, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Rani Therapeutics Holdings, Inc.'s earnings per share (EPS) was highest in 2021 ($-0.42) and lowest in 2023 ($-1.33).
How does Rani Therapeutics Holdings, Inc.'s earnings per share (EPS) compare with similar companies?
Rani Therapeutics Holdings, Inc.'s earnings per share (EPS) ($-0.27) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.